SHR3824 is a novel inhibitor of renal sodium-glucose cotransporter 2, allows an insulin-independent approach to improve type 2 diabetes hyperglycemia. In this single-dose study the investigators evaluated the safety, tolerablity and PK/PD profiles of SHR3824 in healthy subjects.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
84
Shanghai Xuhui Central Hospital
Shanghai, Shanghai Municipality, China
Total 24-hour urinary glucose excretion as a measure of pharmacodynamic effect.
Time frame: 24h after dosing
SHR3824 and its metabolites of concentrations to characterize SHR3824 harmacokinetics.
Time frame: Up to 72h after dosing
The number of patients with adverse events as a measure of safety and tolerability
Time frame: up to day 72h after dosing
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.